Soluble P-selectin, Thrombocytopenia and von Willebrand Factor in HIV Infected Patients

• References

• 1 Tabib A, Greeland T, Mercier I, Loire R, Mornex JF. Coronary lesions in young HIV-positive patients at necropsy. Lancet 1992; 340: 730
• 2 Capron L, Kim YU, Laurin C, Bruneval P, Fiessinger DIN. Atheroembolism in HIV-positive individuals. Lancet 1992; 340: 1039-1040
• 3 Constans J, Marchand JM, Conri C, Peuchant E, Seigneur M, Rispal P, Lasseur C, Pellegrin JL, Leng B. Asymptomatic atherosclerosis in HIV-positive patients: a case-controlled ultrasound study. Ann Med 1995; 27: 683-685
• 4 Cotte JR, Lackner R, Xenig P, Pillary G. Deep vein thrombosis in patients with AIDS. NY State J Med 1990; 20: 159-161
• 5 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
• 6 Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilichini R, Aubert L, Tamalet C, Juhan-Vague I, Gastaut JA. Endothelial cell dysfunction in HIV infection. J AIDS 1992; 5: 127-131
• 7 Cenacchi G, Re MC, Pasquinelli G, Furlini G, Apkarian RP, La PlaceM, Martinelli GN. Human immunodeficiency virus type-1 (HIV-1) infection of endothelial cells in vitro: a virological, ultrastructural and immuno- cytochemical approach. J Submicrosc Cytol Pathol 1992; 24 (02) 155-161
• 8 Teitel J, Shore A, Read SE, Shiavone A. Immune function of vascular endothelial cells is impaired by HIV. J Infect Dis 1989; 160 (03) 551-552
• 9 Schved JF, Gris JC, Arnaud A, Martinez P, Sanchez N, Wautier JL, Sarlat C. von Willebrand factor antigen, tissue type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1 related clinical disease: Independent prognostic relevance of tissue type plasminogen activator. J Lab Clin Med 1992; 120: 411-419
• 10 Blann AD, McCollum CN. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vase Surg 1994; 08: 10-15
• 11 Louache F, Bettaieb A, Henri A, Oskenhendler E, Farcet JP, Bierling P, Seligmann M, Vainchenker W. Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenia purpura. Blood 1991; 78: 2697-2705
• 12 Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation?. Atherosclerosis 1997; 125: 135-138
• 13 Cahill MR, Newland AC. Platelet activation in coronary artery disease. Br J Biomed Sci 1993; 50: 221-234
• 14 Seigneur M, Constans J, Blann A, Renard M, Pellegrin JL, Amiral J, Boisseau M, Conri C. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77: 646-649
• 15 Guerin V, Morlat P, Chene G, Grobost F, Aubertin J, Boisseau M. High levels of plasmatic von Willebrand factor limits the bleeding time in thrombocytopenic HIV-infected patients. Thromb Haemost 1995; 74: 803-804
• 16 Dominguez A, Gamallo G, Garcia R, Lopez-Pastor A, Pena JM, Vazquez J. Pathophysiology of HIV related thrombocytopenia: an analysis of 41 patients. J Clin Pathol 1994; 47: 999-1003
• 17 Bettaieb A, Fromot P, Louache F, Oksenhendler E, Vainchenker W, Duedari N, Bierling P. Presence of cross-reactive antibody between HIV and platelet glycoprotein in HIV-related immune thrombocytopenic purpura. Blood 1992; 80: 262-269